Stock Rating Downgrade The Value Trend Rating for Medtronic PLC (NYSE: MDT) weakened recently from C to D reflecting eroding fundamentals and low Appreciation Potential. Details supporting this lower rating are included in our next […]
For its second fiscal quarter (ending June 30), Integra LifeSciences Holdings Co (NASDAQ: IART) has reported E.P.S. of $-0.16 compared to $0.05 a year ago. For the latest four quarters through June 30, E.P.S. were […]
Harmonic Inc (NASDAQ: HLIT) has reported E.P.S. of $-0.11 for its second fiscal quarter (ending June 30) versus $0.01 for the same period a year ago. E.P.S. were $0.51 for the latest four quarters through […]
Stock Rating Downgrade In recent days the Value Trend Rating for F5 Inc (NASDAQ: FFIV) weakened from C to D reflecting eroding fundamentals and low Appreciation Potential. Recent Price Action On 7/29/24, F5 Inc (NASDAQ: […]
Stock Rating Downgrade Reflecting eroding fundamentals and low Appreciation Potential, the Value Trend Rating for Uranium Energy Corp (NYSEAMERICAN: UEC) weakened during the last several trading days. UEC’s current Value Trend Rating is D and […]
Stock Rating Downgrade Reflecting eroding fundamentals and low Appreciation Potential, the Value Trend Rating for Orchid Island Capital Inc (NYSE: ORC) weakened of late. ORC’s current Value Trend Rating is D and the prior Rating […]
DexCom Inc (NASDAQ: DXCM) stock closed at $64.00 on 7/26/24 after a major decline of -40.7%. Moreover, trading volume in this decline was exceptionally high at 1365% of normal. The stock has declined -42.2% during […]
For its second fiscal quarter (ending June 30), Tompkins Financial Corp (NYSEAMERICAN: TMP) has reported E.P.S. of $1.10 compared to $0.59 a year ago. For the latest four quarters through June 30, E.P.S. were $1.01 […]
Cable One Inc (NYSE: CABO) stock enjoyed a major increase of 14.6% on 7/26/24. The shares closed at $395.01. Moreover, exceptionally high trading volume at 204% of normal accompanied the advance. The stock has been […]
For its second fiscal quarter (ending June 30), Bristol-Myers Squibb Co (NYSE: BMY) has reported E.P.S. of $0.83 compared to $0.99 a year ago. For the latest four quarters through June 30, E.P.S. were $-3.24 […]
Privacy Statement Terms Of Use ©2024 PriceTarget Research